Lung adenocarcinoma: Lessons in translation from bench to bedside

Mount Sinai Journal of Medicine

Volumn 77, Issue 6, 2010, Pages 597-605

  Sangodkar, Jaya ^a   Katz, Suzanna ^a   Melville, Heather ^a   Narla, Goutham ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

genomics; lung cancer; targeted molecular therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MOTESANIB; PACLITAXEL; PANITUMUMAB; PEMETREXED; SORAFENIB; SUNITINIB; VANDETANIB;

CANCER GROWTH; CAUSE OF DEATH; CLINICAL TRIAL; DRUG TARGETING; GENE MUTATION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649684749     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20226     Document Type: Review

References (70)

1. Spira A, Ettinger DS., Drug therapy: multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-392. (Pubitemid 38101633)
2. Sharma SV, Bell DW, Settleman J, et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
3. Minna JD, Roth JA, Gazdar AF., Focus on lung cancer. Cancer Cell 2002; 1: 49-52.
4. Raz DJ, Zell JA, Ou SHI, et al., Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007; 132: 193-199.
5. Manser R, Wright G, Hart D, et al., Surgery for local and locally advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2005; 1: CD004699.
6. Thomas KW, Gould MK., Diagnosis and staging of non-small cell lung cancer. In:, Basow DS, ed. UpToDate. Waltham, MA: UpToDate; 2010.
7. Holmes CE, Ruckdeschel JC, Johnston M, et al., Randomized trial of lobectomy versus limited resection for T1 N0 non-small-cell lung cancer. Ann Thorac Surg 1995; 60: 615-622.
8. Yan TD, Black D, Bannon PG, et al., Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol 2009; 27: 2553-2562.
9. Mentzer SJ, DeCamp MM, Harpole DH Jr, et al., Thoracoscopy and video-assisted thoracic surgery in the treatment of lung cancer. Chest 1995; 107 (6 suppl): 298S-301S.
10. Doddoli C, D'Journo B, Le Pimpec-Barthes F, et al., Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg 2005; 80: 2032-2040.
11. Niiranen A, Niitamokorhonen S, Kouri M, et al., Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 1992; 10: 1927-1932.
12. Hanna N., Adjuvant systemic therapy in resectable non-small cell lung cancer. In:, Basow DS, ed. UpToDate. Waltham, MA: UpToDate; 2010.
13. Scott WJ, Howington J, Feigenberg S, et al., Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 234S-242S. (Pubitemid 47502810)
14. Beer DG, Kardia SL, Huang CC, et al., Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-824.
15. Fry WA, Phillips JL, Menck HR., Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86: 1867-1876.
16. Schild SE, Ramalingam SS., Management of stage III non-small cell lung cancer. In:, Basow DS, ed. UpToDate. Waltham, MA: UpToDate; 2010.
17. Osaki T, Sugio K, Hanagiri T, et al., Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg 2003; 75: 1745-1751.
18. Port JL, Korst RJ, Lee PC, et al., Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? Ann Thorac Surg 2007; 83: 397-400.
19. Lilenbaum R, Samuels M, Taffaro-Neskey M, et al., Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 837-840.
20. Bunn PA Jr,. Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol 1992; 19 (1 suppl 2): 1-11.
21. Bunn PA., The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 1989; 16: 10-21.
22. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al., Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12 (20 part 1): 6049-6055.
23. Roswit B, Patno ME, Rapp R, et al., The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968; 90: 688-697.
24. Antonadou D, Throuvalas N, Petridis A, et al., Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 57: 402-408. (Pubitemid 37040936)
25. Leong SS, Tan EH, Fong KW, et al., Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003; 21: 1767-1774.
26. Senzer N., A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Semin Oncol 2002; 29 (6 suppl 19): 38-41.
27. Antonadou D, Coliarakis N, Synodinou M, et al., Randomized phase III trial of radiation treatment + /- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 915-922.
28. Koukourakis MI, Kyrias G, Kakolyris S, et al., Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000; 18: 2226-2233.
29. Shepherd FA, Pereira JR, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
30. Shepherd FA, Dancey J, Ramlau R, et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
31. Hanna N, Shepherd FA, Fossella FV, et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
32. Fossella FV, DeVore R, Kerr RN, et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
33. Triano LR, Deshpande H, Gettinger SN., Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 2010; 70: 167-179.
34. Sheth S., Current and emerging therapies for patients with advanced non-small-cell lung cancer. Am J Health Syst Pharm 2010; 67 (1 suppl 1): S9-S14.
35. Scagliotti GV, Parikh P, von Pawel J, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
36. Peterson P, Park K, Fossella FV, et al., Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2 (suppl 4): S851.
37. Farray D, Mirkovic N, Albain KS., Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005; 23: 3257-3269.
38. Laurie NA, Donovan SL, Shih CS, et al., Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66.
39. Knudsen ES, Knudsen KE., Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8: 714-724.
40. Croce CM., Molecular origins of cancer: oncogenes and cancer. N Engl J Med 2008; 358: 502-511.
41. Olsen JV, Blagoev B, Gnad F, et al., Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 127: 635-648.
42. Rikova K, Guo A, Zeng Q, et al., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
43. Pao W, Miller VA., Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-2568.
44. Oda K, Matsuoka Y, Funahashi A, et al., A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; doi:10.1038/msb4100014.
45. Korpanty G, Smyth E, Sullivan LA, et al., Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med 2010; 235: 3-9.
46. Natale RB., Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2008; 3 (6 suppl 2): S128-S130.
47. Herbst RS., Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-26.
48. Downward J., Targeting ras signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
49. Hennessy BT, Smith DL, Ram PT, et al., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
50. Ciardiello F, Tortora G., Drug therapy: EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
51. Joy AA, Butts CA., Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer. Clin Lung Cancer 2009; 10 (suppl 1): S24-S29.
52. Pirker R, Pereira JR, Szczesna A, et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
53. Lynch TJ, Patel T, Dreisbach L, et al., Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-917.
54. Socinski MA., Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 2007; 13 (15 part 2): S4597-S4601.
55. Crawford J, Sandler AB, Hammond LA, et al., ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22 (suppl 14S):abstract 7083.
56. Blumenschein G Jr, Sandler A, O'Rourke T, et al., Safety and pharmacokinetics of AMG 706, panitumumab, and carboplatin/paclitaxel for the treatment of patients with advanced non-small cell lung cancer. J Clin Oncol 2006; 24 (suppl 18S):abstract 7119.
57. Kumar B, Cordell KG, Lee JS, et al., Clinical implications of EGFR expression, HPV titer, and smoking status in advanced stage oropharyngeal squamous cell carcinoma patients. Int J Biol Markers 2007; 22: 67.
58. Tsao MS, Sakurada A, Cutz JC, et al., Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
59. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
60. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
61. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
62. Shigematsu H, Gazdar AF., Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-262.
63. Zhou S, Ren S, Yan L, et al., Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 2009; 14: 709-715.
64. Kosaka T, Yatabe Y, Endoh H, et al., Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-8923.
65. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
66. Politi K, Zakowski MF, Fan PD, et al., Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510.
67. Yun CH, Mengwasser KE, Toms AV, et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070-2075.
68. Politi K, Fan PD, Shen R, et al., Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 2010; 3: 111-119.
69. Sos ML, Koker M, Weir BA, et al., PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256-3261.
70. La Monica S, Galetti M, Alfieri RR, et al., Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 2009; 78: 460-468.